Tromsø, Norway, January 30[th] 2024 - ArcticZymes Technologies ASA (OSE:AZT)
announces the launch of Salt Active Nuclease High Quality GMP Grade (SAN HQ
GMP).

SAN HQ GMP from ArcticZymes offers a technically superior solution for the
enzymatic removal of contaminating DNA from therapeutic products such as viral
vectors and vaccines. With the new SAN HQ GMP, ArcticZymes extends its portfolio
to include a GMP-grade nuclease.

ArcticZymes recognizes the challenges faced by bio-manufacturers in the advanced
therapies sector. To streamline the supplier and material qualification process
and to enhance compliance for pharmaceutical industry clients, SAN HQ GMP serves
as a superior solution. The inclusion of a US FDA DMF further facilitates
regulatory submission.

SAN HQ GMP not only offers a technically superior option for enzymatic
applications and provides a more straightforward supplier qualification process
for customers. By reducing risks and minimizing resource expenditure on external
product qualification, the new SAN HQ GMP ensures that clients in the
pharmaceutical industry can access the most cutting-edge solution without
compromising on compliance.

The new SAN HQ GMP will be available for ordering in the second half of February
2024.

CEO Michael B. Akoh comments:

"Today we are announcing the launch of SAN HQ GMP. The novel biomanufacturing
enzyme is our first GMP grade enzyme. It is a testament of our commitment to
current and future clients by offering a technically superior GMP grade solution
for the enzymatic removal of contaminating DNA from therapeutic products such as
viral vectors and vaccines. We are fully committed to continue developing new
novel GMP grade enzymes to facilitate the manufacturing of advanced therapeutics
while having the highest level of compliance."